Literature DB >> 88492

Mouse protection test for group B Streptococcus type III.

R S Baltimore, D L Kasper, J Vecchitto.   

Abstract

The mouse model has been used previously for the study of protection against challenge with strains of group B Streptococcus types Ia, Ib, and Ic, but investigators have not yet been successful in causing lethal disease when type III strains are inoculated. In this study, six clinical isolates belonging to serotype III were lethal in seven-week-old outbred albino mice; the 50% lethal dose (LD50) for mice tested ranged from 1.8 x 10(4) to 4.6 x 10(6). In contrast, a laboratory prototype strain of serotype III was not lethal. The lethality observed with this protection test depended on both the volume of the inoculum given and the medium in which the streptococci were suspended. LD50 values decreased as the volume of the inoculum, given intraperitoneally, increased, up to a volume of 1.5 ml. Hyperimmune rabbit antiserum to a clinical isolate of type III protected mice against an estimated 90% lethal dose of the isolate. Normal rabbit serum and heterologous antisera, except for one of two antisera to type Ia organisms, were not protective. Absorption of type III antiserum with whole organisms of serotype III or with purified, type III-specific polysaccharide inhibited protection of mice against type III organisms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88492     DOI: 10.1093/infdis/140.1.81

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Passive protection by human sera in mice against challenge with strains of group B streptococci.

Authors:  Y Ichiman; K Yoshida
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

4.  Biosynthetic capacity for type-specific antigen synthesis determines the virulence of serotype III strains of group B streptococci.

Authors:  M K Yeung; S J Mattingly
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.

Authors:  C J Baker; M S Edwards; B J Webb; D L Kasper
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Properties of a hemolysin produced by group B streptococci.

Authors:  B A Marchlewicz; J L Duncan
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

7.  Variations in the opsonic requirements of group B streptococcus type III.

Authors:  M J Hastings; C S Easmon
Journal:  Br J Exp Pathol       Date:  1981-10

8.  Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci).

Authors:  C von Hunolstein; S D'Ascenzi; B Wagner; J Jelínková; G Alfarone; S Recchia; M Wagner; G Orefici
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Mouse protection assay for group B streptococcus type III.

Authors:  D O Fleming
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

10.  Isolation, chemical composition, and molecular size of extracellular type II and type Ia polysaccharides of group B streptococci.

Authors:  B J De Cueninck; T F Greber; T K Eisenstein; R M Swenson; G D Shockman
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.